Hello, and welcome to the DeBosch Lab! We study hepatic and enterocyte determinants of metabolic syndrome and non-alcoholic fatty liver disease.
- Dr. DeBosch was awarded a grant from the Longer Life Foundation to study the liver's interactions with heart growth and function!
- Yiming Zhang (Technician II) just got a paper in press at Autophagy: "Transcription Factor EB (TFEB)-dependent Induction of Thermogenesis by the Hepatocyte Solute Carrier 2A (SLC2A) inhibitor, Trehalose".
- Cassie Higgins' manuscript, "Hepatic ALOXE3 is induced during the murine adaptive fasting response, and enhances insulin sensitivity by activating hepatic PPAR-gamma" is in press at the Journal of Clinical Investigation Insight!
- Allyson Mayer was awarded the 2018 Jakschik Award for outstanding Doctoral Thesis work in metabolism!
- Paul Hruz and Brian DeBosch were named winners of the 2018 LEAP Inventors Challenge at Washington University for their invention, Selective Novel Treatment of Fatty Liver Disease
- Allyson Mayer (DBBS Student, Developmental, Stem Cell & Regenerative Medicine) defended her thesis in May 2018 (5 year completion time). She completes her time in the DeBosch Lab as an Spencer and Ann Olin Fellow, a Jakschik Prize winner, and a National Science Foundation Graduate Research Fellowship Awardee.
- Emily Feng, BS (WUSTL ArtSci 2016), DeBosch Lab Alum, enrolled at Kansas University School of Medicine
- Oyin Adenekan (WUSTL ArtSci 2020) was awarded an HHMI undergraduate research fellowship (2018)
- The DeBosch Lab's discoveries: Featured in Science Signaling's 2016 "Signaling Breakthroughs of the Year" (2017).